Table 1.
Baseline characteristics prior to and after propensity score matching.
| Prior to matching | After propensity score matching | |||
|---|---|---|---|---|
| All | UGH | Control group | p | |
| n = 62 | n = 16 | n = 32 | ||
| Age (years) | 60 (16) | 65 (17) | 65 (15) | 0.780 |
| Sex (female) | 25 (40%) | 5 (31%) | 11 (34%) | 1.000 |
| BMI (kg/m2) | 25 (6) | 25 (7) | 25 (6) | 0.624 |
| ASA ≥ 3 | 23 (37%) | 4 (25%) | 10 (31%) | 0.665 |
| Liver cirrhosis | 4 (7%) | 1 (6%) | 1 (6%) | 1.000 |
| Alcohol | 1 (2%) | 1 (6%) | 0 | 0.310 |
| Smoking | 13 (21%) | 6 (38%) | 2 (13%) | 0.220 |
| Diabetes | 4 (7%) | 1 (6%) | 1 (6%) | 1.000 |
| Pathology | ||||
| CRLM | 25 (40%) | 5 (31%) | 15 (47%) | 0.363 |
| HCC | 14 (23%) | 4 (25%) | 8 (25%) | 1.000 |
| ICCA | 9 (15%) | 5 (15%) | 3 (19%) | 1.000 |
| Other malig | 5 (8%) | 2 (13%) | 2 (6%) | 1.000 |
| FNH | 0 | 0 | 0 | |
| Adenoma | 4 (7%) | 2 (13%) | 1 (3%) | 0.106 |
| Hemangioma | 2 (3%) | 0 | 0 | |
| Other benign | 0 | 0 | 0 | |
| IWATE score | 10 (1) | 10 (2) | 10 (2) | 0.937 |
| Neoadjuvant systemic therapy | 13 (21%) | 2 (13%) | 5 (16%) | 0.700 |
Values are expressed as percentage or median with interquartile range